IAP6 Rec'd PCT/PTO 11 JUL 2006

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| TRANSMITTAL LETTER TO THE UNITED STATES | | | ATTORNEY'S DOCKET NUMBER | | | | |
|---|---|---|--|--|--|--|--|
| DESIGNATED/ELECTED OFFICE (DO/EO/US) | | | SPSUP0100WOUS U.S. ABPLICATION NO (FERION ASSESSED TO CFR 1.5) | | | | |
| CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 | | | 10//00//15 | | | | |
| | FIONAL APPLICATION NO. 2004/000541 | INTERNATIONAL FILING DATE 30 December 2004 | PRIORITY DATE CLAIMED 15 January 2004 | | | | |
| TITLE OF | INVENTION | | | | | | |
| | ANTITUMORAL AND ANTIVIRAL PEPTIDES APPLICANT(S) FOR DO/EO/US | | | | | | |
| Sergey I. Chernysh and German P. Bekker | | | | | | | |
| Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: | | | | | | | |
| 1. 🗹 1 | This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. | | | | | | |
| 2. 🔲 1 | This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. | | | | | | |
| | This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. | | | | | | |
| | The US has been elected (Article 31). | | | | | | |
| 5. | A copy of the International Application as filed (35 U.S.C. 371(c)(2)) | | | | | | |
| | a. is attached hereto (required only if not communicated by the International Bureau). | | | | | | |
| | b. | | | | | | |
| | | cation was filed in the United States Receiving | | | | | |
| 6. | An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). | | | | | | |
| | a. is attached hereto. | | | | | | |
| | b. L.J has been previously submitted under 35 U.S.C. 154(d)(4). | | | | | | |
| 7. | Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) | | | | | | |
| | a. are attached hereto (required only if not communicated by the International Bureau). | | | | | | |
| | b. — have been communicated by the International Bureau. c. — have not been made; however, the time limit for making such amendments has NOT expired. | | | | | | |
| | d. have not been made and will not be made. | | | | | | |
| 8. 🔲 | An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). | | | | | | |
| 9. 🗸 | An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). | | | | | | |
| 10. | An English language translation of the Article 36 (35 U.S.C. 371(c)(5)). | e annexes of the International Preliminary E | examination Report under PCT | | | | |
| Items | 11 to 20 below concern document(s |) or information included: | | | | | |
| 11. 🗌 | An Information Disclosure Statement | under 37 CFR 1.97 and 1.98. | | | | | |
| 12. | An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. | | | | | | |
| 13. | A preliminary amendment. | | | | | | |
| 14. | An Application Data Sheet under 37 CFR 1.76. | | | | | | |
| 15. | A substitute specification. | | | | | | |
| 16. | A power of attorney and/or change of address letter. | | | | | | |
| 17. | A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. | | | | | | |
| 18. | A second copy of the published International Application under 35 U.S.C. 154(d)(4). | | | | | | |
| 19. 🗀 | A second copy of the English language | ge translation of the international application | n under 35 U.S.C. 154(d)(4). | | | | |

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IAPS Rec'd PCT/PTO 11 JUL 2006

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007, OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| U.S. APPLICATION NO. (if known see 37 CFR 15) | INTERNATIONAL AP | PLICATION NO. | ATTORNEY'S DOC | KET NUMBER | |
|---|--|-----------------------|-------------------|----------------|--|
| 10/205/15 | PCT/RU2004/00054 | 1 | SPSUP0100WOUS | | |
| Other items or information: The CD enclosed contains the amino acid sequence in computer readable format as required by 37 CFR § 1.821(e). | | | | | |
| Machine Forn | nat: IBM-PC | | | | |
| Operating Sys File on disc: | stem: MS-Windows Sequence Listing.txt | 3 495 hytes create | d on July 7, 2006 | | |
| The following fees have been submitted | Ocquerice Listing.ix | , 0,400 bytes, create | CALCULATIONS | PTO USE ONLY | |
| 21. X Basic national fee (37 CFR 1.492(a)) | ••••• | \$300 | \$ | T TO GOL GIVE! | |
| 22. X Examination fee (37 CFR 1.492(c)) | 79.75 | | 300 | | |
| | . | | | | |
| If the written opinion prepared by ISA/US or the internation by IPEA/US indicates all claims satisfy provision | • | | | | |
| All other situations | 200 | | | | |
| 23. Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International | proliminant avamination can | art necessariation | | | |
| IPEA/US indicates all claims satisfy provisions | \$ | | | | |
| Search fee (37 CFR 1.445(a)(2)) has been paid on the International Searching Authority | | \$100 | Ф | | |
| International Search Report prepared by an ISA other previously communicated to the US by the IB | | | | | |
| All other situations. | | | 400 | | |
| TOTAL OF 21, 22 and 23 = | 900 | | | | |
| Additional fee for specification and drawings filed i sequence listing in compliance with 37 CFR 1. | | | | | |
| electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of | | | | | |
| | | | | | |
| | Number of each additional 50 or fraction RATE thereof (round up to a whole number) | | | | |
| - 100 = /50 = | | × \$250 | \$ | | |
| Surcharge of \$130.00 for furnishing any of the search after the date of commencement of the national stage | \$ | | | | |
| CLAIMS NUMBER FILED | NUMBER EXTRA | RATE | \$ | | |
| Total claims 26 - 20 = | 6 | x \$50 | \$ 300 | | |
| Independent claims 1 -3 = | 0 | x \$200 | \$ | | |
| MULTIPLE DEPENDENT CLAIM(S) (if applicable) | \$ | | | | |
| | CALCULATIONS = | \$ 1200 | | | |
| Applicant claims small entity status. See 37 CFR 1 | | | | | |
| | \$ 600 | | | | |
| Processing fee of \$130.00 for furnishing the English tra- claimed priority date (37 CFR 1.492(i)). | \$, | | | | |
| | \$ 600 | | | | |
| Fee for recording the enclosed assignment (37 CFR 1. by an appropriate cover sheet (37 CFR 3.28, 3.31). \$4 | \$ | | | | |
| | \$ 600 | | | | |
| į | Amount to be refunded: | \$ | | | |
| 7, | Amount to be charged | \$ | | | |

IAP6 Rec'd PCT/PTO 11 JUL 2006

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| l | A check in the amount of \$ to cover the above feet is enclosed. | | | | |
|--|---|--|--|--|--|
| a. 🗀 | A check in the amount of \$\frac{1}{2}\$ to cover the above fees is enclosed. | | | | |
| b. 🗀 | Please charge my Deposit Account No. 18-0988 in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed. | | | | |
| c. X | The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 18-0988 . A duplicate copy of this sheet is enclosed. | | | | |
| d. X | Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. | | | | |
| NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status. | | | | | |
| SEND A | ALL CORRESPONDENCE TO: Heidi A. Boehlefeld NAME 34,296 REGISTRATION NUMBER | | | | |

Atty Docket No. SPSUP0100WOUS

ANTITUMORAL AND ANTIVIRAL PEPTIDES

Inventors:

Sergey I. Chernysh and German P. Bekker

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that the attached patent application (along with any other paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on this date, <u>July 11, 2006</u>, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number <u>EV839641585US</u> addressed to the: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Denise G. Bachtel (Typed or Printed Name of Person Mailing Paper)

(Signature of Person Mailing Paper)

VERIFICATION OF TRANSLATION

I, Oleg V. REVINSKIY, of Yan Rainis Blvd. 26-1-155, Moscow 125373, Russia, hereby declare that I am acquainted with both English and Russian languages and that the attached document is a true and correct translation made by me to the best of my knowledge and belief of: "ANTITUMORAL AND ANTIVIRAL PEPTIDES".

O.V. Revinskiy

1205,06